The week in pharma: action, reaction and insight – week to September 19
By Barbara Obstoj-Cardwell
Important research news last week included US biotech aTyr Pharma posting disappointing Phase III results for its efzofitimod in pulmonary sarcoidosis, while Switzerland-based Roivant announced positive Phase III data on its dermatomyositis candidate brepocitinib. On the M&A front, Swiss pharma giant Roche announced plans to acquire US biotech 89bio and its liver disease candidate pegozafermin. Also of note, the US government’s vaccines advisory committee – ACIP -meeting last week adds to uncertainty over immunization policy.
aTyr Pharma EFZO-FIT falls flat
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze